Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19566998 | 0.96 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19566983 | 0.95 | TSHR (0.61) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19549085 | 0.92 | MAPT (0.62) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19549109 | 0.92 | TSHR (0.62) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19578932 | 0.91 | TSHR (0.62) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19549110 | 0.89 | LMNA (0.62) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19566995 | 0.89 | LMNA (0.62) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19566994 | 0.88 | TSHR (0.64) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL17713895 | 0.88 | LMNA (0.63) | TSHRSMN1; SMN2LMNAHTTALDH1A1 | |
| SCHEMBL19549066 | 0.88 | LMNA (0.75) | TSHRSMN1; SMN2LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212644-B1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF DIABETES | APOGLYX AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3212644-B1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF DIABETES | APOGLYX AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-107001351-B | Derivatives of 2- (1,2, 4-triazol-3-ylsulfanyl) -N-1,3, 4-thiadiazol-2-ylacetamide useful in the treatment of, in particular, diabetes | 阿波格吕克斯有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | AQP1, AQP3, AQP4 | TSHR 2782/4885SMN1; SMN2 4525/4885LMNA 1545/4885 |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | AQP1, AQP3, AQP4 | TSHR 2782/4885SMN1; SMN2 4525/4885LMNA 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.